Material Agreement · New Debt / Obligation

Securities and Exchange Commission on April 4, 2017. The foregoing description of Pershing’s PRH Note does not purport to be complete and is qualified in its entirety by reference to Pershing’s PRH Note, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information disclosed in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Secured Convertible Promissory Note between the Company and Edward V. Pershing, dated July 26, 2018 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 30, 2018 PROVECTUS BIOPHARMACEUTICALS, INC. By: /s/ Timothy C. Scott Timothy C. Scott President